FILTER

Refine your search with the following facets to narrow down your results.

6 Current news of e-Therapeutics

New trial will investigate cancer-fighting properties of cannabinoid

01-Oct-2012 - Chemicals similar to those found in cannabis form the basis of a new drug that is being trialled in UK cancer patients for the first time by researchers at the Cancer Research UK and National Institute for Health Research (NIHR) Experimental Cancer Medicine Centre in Newcastle. The trial – funded ...

cancer cannabinoids cannabis

e-Therapeutics starts second phase I cancer trial of ETS2101

14-Sep-2012 - e-Therapeutics plc announced that it has started a second phase I clinical trial of its anti-cancer drug ETS2101. This trial will enrol up to 45 patients with a variety of solid tumours at two UK centres, St James’s University Hospital in Leeds and the Northern Centre for Cancer Care at the ...

cancer phase I studies

e-Therapeutics’ ETS2101 enters phase I clinical trial in brain cancer

21-Jun-2012 - e-Therapeutics plc announces the start of the first clinical trial evaluating its compound ETS2101 as a treatment for cancer. The phase I trial is enrolling patients with primary brain cancer (glioma) or cancer that has spread to the brain from other sites. Led by Professor Santosh Kesari, MD, ...

brain cancer glioma phase I studies

Celgene Executive Dr Rajesh Chopra joins the Board of e-Therapeutics

07-Feb-2012 - e-Therapeutics plc announced that Dr Rajesh Chopra has joined the Company’s Board as a Non-Executive Director. A clinician and scientist by training, Dr Chopra has since 2009 been Vice President of Translational and Early Drug Development at Celgene Corporation. He leads a group of around 100 ...

e-Therapeutics Appoints Daniel Elger as Chief Financial Officer

14-Jun-2011 - e-Therapeutics plc announced that Dr Daniel Elger will be joining the Company and its Board as Chief Financial Officer, with immediate effect.Dr Elger, 41, was previously the VP, Marketing & Communications at cancer drug developer Antisoma plc. He joined that company in 2002 and served on its ...

e-Therapeutics Board appoints Stephen Self to direct development

08-Dec-2010 - e-Therapeutics plc announced that Steve Self, Development Director, has agreed to join the Board as an Executive Director with immediate effect. Steve began his career in Chemistry in 1975 with The Wellcome Foundation. He held a variety of positions in both R&D and Operations before being ...